Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus — Elizabeth, New Jersey
- Englewood Hospital and Medical Center — Englewood, New Jersey
- Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New Jersey: - Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Englewood Hospital and Medical Center — Englewood, New Jersey
- Virtua Samson Cancer Center — Moorestown, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Riverview Medical Center/Booker Cancer Center — Red Bank, New Jersey
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in New Jersey: - Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus — Elizabeth, New Jersey
- Hackettstown Medical Center — Hackettstown, New Jersey
- The Cancer Institute of New Jersey Hamilton — Hamilton, New Jersey
- Jersey City Medical Center — Jersey City, New Jersey
- Monmouth Medical Center Southern Campus — Lakewood, New Jersey
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in New Jersey: - Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in New Jersey: - Regional Cancer Care Associates LLC — East Brunswick, New Jersey
- Hunterdon Medical Center — Flemington, New Jersey
- Summit Medical Group, P.A. — Florham Park, New Jersey
- Rutgers Health — New Brunswick, New Jersey
- Overlook Medical Center — Summit, New Jersey
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in New Jersey: - Research Site — Belleville, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in New Jersey: - Englewood Hospital — Englewood, New Jersey
- Capital Health Medical Center - Hopewell — Pennington, New Jersey
- Penn Medicine - Princeton Health — Plainsboro, New Jersey
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New Jersey: - Hunterdon Medical Center — Flemington, New Jersey
Phase 3 Recruiting Industry
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…
Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in New Jersey: - Summit Medical Group PA — Florham Park, New Jersey
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey) — Livingston, New Jersey
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey) — Long Branch, New Jersey
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey) — New Brunswick, New Jersey
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey) — Newark, New Jersey
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in New Jersey: - Hackensack Univ Medical Center (HUMC) ( Site 0007) — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0076) — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in New Jersey: - Astera Cancer Care East Brunswick — East Brunswick, New Jersey
- Summit Medical Group — Florham Park, New Jersey
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in New Jersey: - Research Site — Camden, New Jersey
- Research Site — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in New Jersey: - Cooper University Health Care — Camden, New Jersey
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in New Jersey: - Hackensack Meridian Health — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in New Jersey: - New Jersey Cancer Care, PA — Belleville, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0033) — New Brunswick, New Jersey
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
Sponsor: Hoffmann-La Roche
NCT ID: NCT07413939
Sites in New Jersey: - Astera Cancer Care East Brunswick — East Brunswick, New Jersey
Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative…
Sponsor: Daiichi Sankyo
NCT ID: NCT05950945
Sites in New Jersey: - Overlook Medical Center — Summit, New Jersey
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New Jersey: - Hunterdon Medical Center — Flemington, New Jersey
- Monmouth Medical Center Southern Campus — Lakewood, New Jersey
- Cooperman Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in New Jersey: - Overlook Medical Center — Summit, New Jersey
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in New Jersey: - Englewood Hospital and Medical Center — Englewood, New Jersey
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in New Jersey: - MD Anderson Cancer Center at Cooper — Camden, New Jersey
Phase 2 Recruiting Industry
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESA…
Sponsor: GlaxoSmithKline
NCT ID: NCT04641247
Sites in New Jersey: - GSK Investigational Site — Morristown, New Jersey